Repligen (NASDAQ:RGEN) Stock Rating Upgraded by Wall Street Zen

Repligen (NASDAQ:RGEN) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also recently weighed in on RGEN. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, July 30th. HSBC started coverage on Repligen in a report on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price on the stock. Jefferies Financial Group lowered their target price on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, September 12th. Finally, Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $169.62.

Repligen Price Performance

NASDAQ:RGEN opened at $145.24 on Friday. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52. The stock has a 50 day moving average of $125.12 and a two-hundred day moving average of $125.54. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.17 billion, a P/E ratio of -580.94, a price-to-earnings-growth ratio of 2.68 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Martin D. Madaus purchased 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RGEN. Twin Tree Management LP purchased a new stake in shares of Repligen during the first quarter worth $29,000. Hantz Financial Services Inc. increased its position in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares during the period. Signaturefd LLC increased its position in shares of Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares during the period. Center for Financial Planning Inc. increased its position in shares of Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 193 shares during the period. Finally, AlphaQuest LLC purchased a new stake in shares of Repligen during the second quarter worth $104,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.